Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more
Beijing SL Pharmaceutical Co Ltd (002038) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.003x
Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has a cash flow conversion efficiency ratio of -0.003x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-16.39 Million) by net assets (CN¥5.70 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing SL Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beijing SL Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bit Digital Inc
NASDAQ:BTBT
|
-0.229x |
|
VP Bank AG
SW:VPBN
|
-0.989x |
|
Wafer Works
TWO:6182
|
0.005x |
|
Intellian Technologies Inc
KQ:189300
|
-0.031x |
|
Green Dot Corporation
NYSE:GDOT
|
0.026x |
|
Resolute Holdings Management, Inc.
NYSE:RHLD
|
1.433x |
|
Northfield Bancorp Inc
NASDAQ:NFBK
|
0.020x |
|
ASSET WORLD CORP PCL-NVDR
BK:AWC-R
|
0.019x |
Annual Cash Flow Conversion Efficiency for Beijing SL Pharmaceutical Co Ltd (2003–2024)
The table below shows the annual cash flow conversion efficiency of Beijing SL Pharmaceutical Co Ltd from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.58 Billion | CN¥225.49 Million | 0.040x | -48.99% |
| 2023-12-31 | CN¥5.81 Billion | CN¥460.20 Million | 0.079x | +11.33% |
| 2022-12-31 | CN¥5.48 Billion | CN¥389.82 Million | 0.071x | -18.44% |
| 2021-12-31 | CN¥5.33 Billion | CN¥464.63 Million | 0.087x | +4.57% |
| 2020-12-31 | CN¥4.98 Billion | CN¥415.84 Million | 0.083x | -39.59% |
| 2019-12-31 | CN¥4.82 Billion | CN¥665.83 Million | 0.138x | +28.62% |
| 2018-12-31 | CN¥4.52 Billion | CN¥485.17 Million | 0.107x | +21.25% |
| 2017-12-31 | CN¥4.30 Billion | CN¥380.72 Million | 0.089x | -12.31% |
| 2016-12-31 | CN¥3.93 Billion | CN¥396.86 Million | 0.101x | -27.73% |
| 2015-12-31 | CN¥3.61 Billion | CN¥504.87 Million | 0.140x | -4.41% |
| 2014-12-31 | CN¥3.18 Billion | CN¥465.00 Million | 0.146x | +8.93% |
| 2013-12-31 | CN¥2.59 Billion | CN¥347.41 Million | 0.134x | -28.91% |
| 2012-12-31 | CN¥2.11 Billion | CN¥398.60 Million | 0.189x | +39.20% |
| 2011-12-31 | CN¥1.69 Billion | CN¥228.59 Million | 0.136x | -31.02% |
| 2010-12-31 | CN¥1.21 Billion | CN¥238.13 Million | 0.197x | +10.81% |
| 2009-12-31 | CN¥983.06 Million | CN¥174.41 Million | 0.177x | -30.38% |
| 2008-12-31 | CN¥762.61 Million | CN¥194.32 Million | 0.255x | +59.16% |
| 2007-12-31 | CN¥551.93 Million | CN¥88.36 Million | 0.160x | +18.56% |
| 2006-12-31 | CN¥426.20 Million | CN¥57.55 Million | 0.135x | +8.78% |
| 2005-12-31 | CN¥382.49 Million | CN¥47.48 Million | 0.124x | +43.52% |
| 2004-12-31 | CN¥361.45 Million | CN¥31.26 Million | 0.086x | -67.43% |
| 2003-12-31 | CN¥115.05 Million | CN¥30.55 Million | 0.266x | -- |